WO1995032739A1 - Cyclodextrin cellular delivery system for oligonucleotides - Google Patents
Cyclodextrin cellular delivery system for oligonucleotides Download PDFInfo
- Publication number
- WO1995032739A1 WO1995032739A1 PCT/US1995/006916 US9506916W WO9532739A1 WO 1995032739 A1 WO1995032739 A1 WO 1995032739A1 US 9506916 W US9506916 W US 9506916W WO 9532739 A1 WO9532739 A1 WO 9532739A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- oligonucleotide
- oligonucleotides
- composition
- adamantane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8501182A JPH10501237A (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cell delivery system for oligonucleotides |
AU27643/95A AU2764395A (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cellular delivery system for oligonucleotides |
DE69513395T DE69513395T2 (en) | 1994-06-01 | 1995-06-01 | CELLULAR DELIVERY SYSTEM WITH CYCLODEXTRIN, FOR OLIGONUCLEOTIDES |
DK95922923T DK0762898T3 (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin system for delivery of oligonucleotides to cells |
EP95922923A EP0762898B1 (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cellular delivery system for oligonucleotides |
GR20000400052T GR3032355T3 (en) | 1994-06-01 | 2000-01-13 | Cyclodextrin cellular delivery system for oligonucleotides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25207294A | 1994-06-01 | 1994-06-01 | |
US08/252,072 | 1994-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995032739A1 true WO1995032739A1 (en) | 1995-12-07 |
Family
ID=22954476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/006916 WO1995032739A1 (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cellular delivery system for oligonucleotides |
Country Status (12)
Country | Link |
---|---|
US (3) | US5691316A (en) |
EP (1) | EP0762898B1 (en) |
JP (1) | JPH10501237A (en) |
CN (1) | CN1158088A (en) |
AT (1) | ATE186647T1 (en) |
AU (1) | AU2764395A (en) |
CA (1) | CA2191777A1 (en) |
DE (1) | DE69513395T2 (en) |
DK (1) | DK0762898T3 (en) |
ES (1) | ES2139904T3 (en) |
GR (1) | GR3032355T3 (en) |
WO (1) | WO1995032739A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010005A2 (en) * | 1995-09-12 | 1997-03-20 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
WO2010066908A1 (en) * | 2008-12-12 | 2010-06-17 | Eurogentec S.A. | Use of cyclodextrins to improve the specificity, sensitivity and yield of nucleic acid amplification reactions |
US7807198B2 (en) | 2000-12-19 | 2010-10-05 | California Institute Of Technology | Compositions containing inclusion complexes |
US8252276B2 (en) | 2002-09-06 | 2012-08-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8357377B2 (en) | 2002-10-09 | 2013-01-22 | Suzie Hwang Pun | Cyclodextrin-based materials, compositions and uses related thereto |
US8497365B2 (en) | 2007-01-24 | 2013-07-30 | Mark E. Davis | Cyclodextrin-based polymers for therapeutics delivery |
US9260711B2 (en) | 2012-09-13 | 2016-02-16 | Ge Healthcare Uk Limited | Solid matrix for one step nucleic acid amplification |
US10781175B2 (en) | 2016-07-15 | 2020-09-22 | Am Chemicals Llc | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030099959A1 (en) * | 1995-04-12 | 2003-05-29 | Kandimalla Ekambar R. | Cooperative oligonucleotides |
WO1999041403A1 (en) * | 1998-02-12 | 1999-08-19 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
AUPQ259399A0 (en) * | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
US6716589B2 (en) | 2000-11-20 | 2004-04-06 | Alphabeta Ab | Discordant helix stabilization for prevention of amyloid formation |
US20060199778A1 (en) * | 2001-09-19 | 2006-09-07 | Rutledge Ellis-Behnke | Methods and products related to non-viral transfection |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
IL161733A0 (en) * | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
CA2428740A1 (en) * | 2002-05-20 | 2003-11-20 | Bayer Corporation | Automated method and reagent therefor for assaying body fluid samples such as cerebrospinal fluid (csf) |
US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
US20050147584A1 (en) * | 2004-01-05 | 2005-07-07 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
EP1605978B1 (en) * | 2003-03-07 | 2010-09-01 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
US20070179100A1 (en) * | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
EP1625138A4 (en) | 2003-04-17 | 2010-06-23 | Alnylam Pharmaceuticals Inc | Protected monomers |
CA2542232A1 (en) | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals, Inc. | Method for treating neurodegenerative disease by inhibiting alpha-synuclein |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
US7883688B2 (en) * | 2005-02-03 | 2011-02-08 | Agency For Science, Technology And Research | Polycationic polyrotaxanes capable of forming complexes with nucleic acids |
US20090176729A1 (en) * | 2007-12-14 | 2009-07-09 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
AU2009273878A1 (en) * | 2008-07-25 | 2010-01-28 | Alnylam Pharmaceuticals, Inc. | Enhancement of siRNA silencing activity using universal bases or mismatches in the sense strand |
US20100056612A1 (en) * | 2008-08-06 | 2010-03-04 | Alexander Chucholowski | Molecular entities for binding, stabilization and cellular delivery of charged molecules |
WO2010088282A1 (en) * | 2009-01-30 | 2010-08-05 | Rgo Biosciences Llc | Nucleic acid binding assays |
CN102781237A (en) * | 2009-11-23 | 2012-11-14 | 天蓝制药公司 | Cyclodextrin-based polymers for therapeutic delivery |
US20110218156A1 (en) * | 2010-02-04 | 2011-09-08 | Alexander Chucholowski | Molecular entities for binding, stabilization and cellular delivery of negatively charged molecules |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
EP2683410A2 (en) | 2011-03-08 | 2014-01-15 | Access Pharmaceuticals, Inc. | Targeted nanocarrier systems for delivery of actives across biological membranes |
KR101465365B1 (en) * | 2013-10-15 | 2014-11-25 | 성균관대학교산학협력단 | Lipid-supported polymeric functional particles and method thereof |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US20190177800A1 (en) * | 2017-12-08 | 2019-06-13 | 10X Genomics, Inc. | Methods and compositions for labeling cells |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP3802819A1 (en) * | 2018-05-30 | 2021-04-14 | AXOLABS GmbH | Method for detecting oligonucleotide conjugates |
CN114874358B (en) * | 2022-04-11 | 2023-05-02 | 上海师范大学 | Synthesis method and application of polynuclear cerium nano material |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990000596A1 (en) * | 1988-07-07 | 1990-01-25 | The Trustees Of The University Of Pennsylvania | Method of modulating virus-host cell interactions using carbohydrates and carbohydrate derivatives |
WO1991002040A1 (en) * | 1989-08-04 | 1991-02-21 | Kosak Kenneth M | Cyclodextrin labels for nucleic acid and biochemical analysis |
JPH05170650A (en) * | 1991-12-19 | 1993-07-09 | Sanyo Kokusaku Pulp Co Ltd | Medicinal composition and its production |
WO1993023570A1 (en) * | 1992-05-11 | 1993-11-25 | Pharmagenics, Inc. | Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety |
WO1994001448A1 (en) * | 1992-07-06 | 1994-01-20 | Pharmagenics, Inc. | Oligonucleotides modified with conjugate groups |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5457187A (en) * | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
-
1994
- 1994-11-17 US US08/341,522 patent/US5691316A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 DK DK95922923T patent/DK0762898T3/en active
- 1995-06-01 WO PCT/US1995/006916 patent/WO1995032739A1/en active IP Right Grant
- 1995-06-01 CA CA002191777A patent/CA2191777A1/en not_active Abandoned
- 1995-06-01 CN CN95194366A patent/CN1158088A/en active Pending
- 1995-06-01 AT AT95922923T patent/ATE186647T1/en not_active IP Right Cessation
- 1995-06-01 DE DE69513395T patent/DE69513395T2/en not_active Expired - Fee Related
- 1995-06-01 EP EP95922923A patent/EP0762898B1/en not_active Expired - Lifetime
- 1995-06-01 ES ES95922923T patent/ES2139904T3/en not_active Expired - Lifetime
- 1995-06-01 AU AU27643/95A patent/AU2764395A/en not_active Abandoned
- 1995-06-01 JP JP8501182A patent/JPH10501237A/en not_active Withdrawn
- 1995-06-07 US US08/480,834 patent/US5616565A/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,833 patent/US5605890A/en not_active Expired - Lifetime
-
2000
- 2000-01-13 GR GR20000400052T patent/GR3032355T3/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990000596A1 (en) * | 1988-07-07 | 1990-01-25 | The Trustees Of The University Of Pennsylvania | Method of modulating virus-host cell interactions using carbohydrates and carbohydrate derivatives |
WO1991002040A1 (en) * | 1989-08-04 | 1991-02-21 | Kosak Kenneth M | Cyclodextrin labels for nucleic acid and biochemical analysis |
JPH05170650A (en) * | 1991-12-19 | 1993-07-09 | Sanyo Kokusaku Pulp Co Ltd | Medicinal composition and its production |
WO1993023570A1 (en) * | 1992-05-11 | 1993-11-25 | Pharmagenics, Inc. | Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety |
WO1994001448A1 (en) * | 1992-07-06 | 1994-01-20 | Pharmagenics, Inc. | Oligonucleotides modified with conjugate groups |
Non-Patent Citations (9)
Title |
---|
AGRAWAL, SUDHIR ET AL: "GEM 91 - an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS", ANTISENSE RES. DEV. 1992, VOL. 2, NO. 4, PAGES 261-6 * |
DATABASE DISSERTATION ABSTRACTS UNIVERSITY MICROFILMS INTERNATIONAL; DOUGHERTY, JOSEPH PAUL: "SYNTHESIS AND PROPERTIES OF 2',5'-LINKED DNA, AND SELECTIVE CLEAVAGE OF RNA WITH SYNTHETIC CATALYSTS" * |
DATABASE WPI Section Ch Week 9332, Derwent World Patents Index; Class B02, AN 93-252662 * |
DISSERTATION ABSTRACTS INTERNATIONAL. VOLUME: 56, NUMBER 3, SECTION: B, PAGE: 1420. ABSTRACT OF THESIS (PH.D.), 1995, COLUMBIA UNIVERSITY, 166 PAGES * |
HURAUX J.M. ET AL: "Prospects and current data in antiviral chemotherapy", REV. PNEUMOL. CLIN., 1989, VOL. 45, NO. 3, PAGE(S) 99-105, FRANCE * |
J.L. HOFFMAN ET AL.: "The interaction of cyclodextrins with nucleic acids. A study of secondary structure in three transfer ribonucleic acids", BIOCHEMISTRY, vol. 9, no. 18, pages 3542 - 3550 * |
PATENT ABSTRACTS OF JAPAN vol. 17, no. 577 (C - 1122) 9 July 1993 (1993-07-09) * |
UENO M ET AL: "Arranging quaternary structure of peptides by cyclodextrin-guest inclusion complex: Sequence-specific DNA binding by a peptide dimer with artificial dimerization module", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1993, VOL. 115, NO. 26, PAGE(S) 12575-12576 * |
ZHAO Q ET AL: "Use of cyclodextrin as carrier for oligonucleotides", KEYSTONE SYMPOSIUM ON DRUG DELIVERY: BARRIERS TO DRUG TRANSPORT AND THE DESIGN OF NOVEL THERAPEUTIC AGENTS, HILTON HEAD ISLAND, SOUTH CAROLINA, USA, JANUARY 7-13, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT, 1995, SUPPL. 19A, PAGE(S) 176. * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010005A3 (en) * | 1995-09-12 | 1997-06-26 | Hybridon Inc | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US6667293B1 (en) | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
WO1997010005A2 (en) * | 1995-09-12 | 1997-03-20 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
US8277846B2 (en) | 2000-12-19 | 2012-10-02 | California Institute Of Technology | Complexing agents for compositions containing inclusion complexes |
US7807198B2 (en) | 2000-12-19 | 2010-10-05 | California Institute Of Technology | Compositions containing inclusion complexes |
US7968123B2 (en) | 2000-12-19 | 2011-06-28 | California Institute Of Technology | Complexing agents for compositions containing inclusion complexes |
US8092833B2 (en) | 2000-12-19 | 2012-01-10 | California Institute Of Technology | Compositions containing inclusion complexes |
US8404662B2 (en) | 2002-09-06 | 2013-03-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8518388B2 (en) | 2002-09-06 | 2013-08-27 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8314230B2 (en) | 2002-09-06 | 2012-11-20 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8680202B2 (en) | 2002-09-06 | 2014-03-25 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8389499B2 (en) | 2002-09-06 | 2013-03-05 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8399431B2 (en) | 2002-09-06 | 2013-03-19 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8252276B2 (en) | 2002-09-06 | 2012-08-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8475781B2 (en) | 2002-09-06 | 2013-07-02 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8609081B2 (en) | 2002-09-06 | 2013-12-17 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US9550860B2 (en) | 2002-09-06 | 2017-01-24 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580242B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580244B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580243B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8603454B2 (en) | 2002-09-06 | 2013-12-10 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8357377B2 (en) | 2002-10-09 | 2013-01-22 | Suzie Hwang Pun | Cyclodextrin-based materials, compositions and uses related thereto |
US8497365B2 (en) | 2007-01-24 | 2013-07-30 | Mark E. Davis | Cyclodextrin-based polymers for therapeutics delivery |
US9610360B2 (en) | 2007-01-24 | 2017-04-04 | Ceruliean Pharma Inc. | Polymer drug conjugates with tether groups for controlled drug delivery |
WO2010066908A1 (en) * | 2008-12-12 | 2010-06-17 | Eurogentec S.A. | Use of cyclodextrins to improve the specificity, sensitivity and yield of nucleic acid amplification reactions |
US9260711B2 (en) | 2012-09-13 | 2016-02-16 | Ge Healthcare Uk Limited | Solid matrix for one step nucleic acid amplification |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
US10781175B2 (en) | 2016-07-15 | 2020-09-22 | Am Chemicals Llc | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates |
US11447451B2 (en) | 2016-07-15 | 2022-09-20 | Am Chemicals Llc | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates |
Also Published As
Publication number | Publication date |
---|---|
ATE186647T1 (en) | 1999-12-15 |
US5691316A (en) | 1997-11-25 |
DE69513395T2 (en) | 2000-07-27 |
AU2764395A (en) | 1995-12-21 |
US5605890A (en) | 1997-02-25 |
JPH10501237A (en) | 1998-02-03 |
CN1158088A (en) | 1997-08-27 |
US5616565A (en) | 1997-04-01 |
EP0762898A1 (en) | 1997-03-19 |
DE69513395D1 (en) | 1999-12-23 |
EP0762898B1 (en) | 1999-11-17 |
GR3032355T3 (en) | 2000-04-27 |
CA2191777A1 (en) | 1995-12-07 |
ES2139904T3 (en) | 2000-02-16 |
DK0762898T3 (en) | 2000-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0762898B1 (en) | Cyclodextrin cellular delivery system for oligonucleotides | |
ZHAO et al. | Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery | |
Dong et al. | Strategies, design, and chemistry in siRNA delivery systems | |
EP0664833B1 (en) | Therapeutic anti-hiv oligonucleotide and pharmaceutical | |
RU2558258C2 (en) | Sirna conjugate and method for producing it | |
CN103747805B (en) | For treating, delaying and/or preventing human genetic disease's such as type of steirert-Batten-Gibb syndrome 1(DM1)Compound | |
EP2691118B1 (en) | Perfluorinated compounds for the non-viral transfer of nucleic acids | |
CN107849567A (en) | A kind of siRNA, the pharmaceutical composition containing the siRNA and conjugate and their application | |
EP2264167B1 (en) | Double-stranded lipid-modified rna having high rna interference effect | |
US20080051323A1 (en) | Chloroquine drug compositions and methods for their synthesis | |
WO1998002448A1 (en) | Conjugates of minor groove dna binders with antisense oligonucleotides | |
EP0537299A1 (en) | Oligonucleotide-transport agent disulfide conjugates | |
WO1994008004A9 (en) | Therapeutic anti-hiv oligonucleotide and pharmaceutical | |
US20050153913A1 (en) | Nucleic acid carrier compositions and methods for their synthesis | |
Abdou et al. | Beta-cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence | |
Habus et al. | Synthesis, Hybridization Properties, Nuclease Stability, and Cellular Uptake of the Oligonucleotide-Amino-. beta.-cyclodextrins and Adamantane Conjugates | |
US20030166512A1 (en) | Protein carrier system for therapeutic oligonucleotides | |
US20060040879A1 (en) | Chloroquine coupled nucleic acids and methods for their synthesis | |
EP0850070B1 (en) | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response | |
CN114681619B (en) | Aptamer complex based on Biotin-SA and application thereof | |
Zhao et al. | Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs | |
EP4286416A1 (en) | Carrier for functional nucleic acid and protein introduction | |
WO1995020404A1 (en) | Triplex-forming paired-ion oligonucleotides and methods for preparing and using same | |
AU2003236659B2 (en) | Cooperative oligonucleotides | |
Hsu | In Vivo Studies of DNA Nanostructures and Synthesis of Long, Repetitive DNA Sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194366.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CN CZ DE DK EE FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2191777 Country of ref document: CA Ref document number: 1995922923 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 288420 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1995922923 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995922923 Country of ref document: EP |